CR20210134A - Anticuerpos agonistas contra cd200r y sus usos - Google Patents

Anticuerpos agonistas contra cd200r y sus usos

Info

Publication number
CR20210134A
CR20210134A CR20210134A CR20210134A CR20210134A CR 20210134 A CR20210134 A CR 20210134A CR 20210134 A CR20210134 A CR 20210134A CR 20210134 A CR20210134 A CR 20210134A CR 20210134 A CR20210134 A CR 20210134A
Authority
CR
Costa Rica
Prior art keywords
cd200r
agonist antibodies
antibodies against
gvhd
ibd
Prior art date
Application number
CR20210134A
Other languages
English (en)
Spanish (es)
Inventor
Anja Koester
Payal Mehta
Diana Isabel Ruiz
Derrick Ryan Witcher
Xiufeng Wu
Stephen John Demarest
Scott Charles Potter
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20210134A publication Critical patent/CR20210134A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72Increased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CR20210134A 2018-09-14 2019-09-11 Anticuerpos agonistas contra cd200r y sus usos CR20210134A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862731204P 2018-09-14 2018-09-14
PCT/US2019/050511 WO2020055943A1 (en) 2018-09-14 2019-09-11 Cd200r agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CR20210134A true CR20210134A (es) 2021-03-29

Family

ID=68051977

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210134A CR20210134A (es) 2018-09-14 2019-09-11 Anticuerpos agonistas contra cd200r y sus usos

Country Status (27)

Country Link
US (2) US11319370B2 (enExample)
EP (1) EP3849667A1 (enExample)
JP (3) JP7185051B2 (enExample)
KR (1) KR102705378B1 (enExample)
CN (2) CN118530360A (enExample)
AR (1) AR116668A1 (enExample)
AU (1) AU2019339334B2 (enExample)
BR (1) BR112021003254A2 (enExample)
CA (1) CA3112763C (enExample)
CL (1) CL2021000606A1 (enExample)
CO (1) CO2021003093A2 (enExample)
CR (1) CR20210134A (enExample)
DO (1) DOP2021000040A (enExample)
EA (1) EA202190530A1 (enExample)
EC (1) ECSP21017619A (enExample)
IL (1) IL281442B2 (enExample)
JO (1) JOP20210048B1 (enExample)
MA (1) MA53604A (enExample)
MX (1) MX2021003026A (enExample)
MY (1) MY196156A (enExample)
NZ (1) NZ773626A (enExample)
PE (1) PE20211742A1 (enExample)
PH (1) PH12021550530A1 (enExample)
SG (1) SG11202101697YA (enExample)
TW (1) TWI749367B (enExample)
WO (1) WO2020055943A1 (enExample)
ZA (2) ZA202101246B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
WO2021243204A1 (en) * 2020-05-29 2021-12-02 23Andme, Inc. Anti-cd200r1 antibodies and methods of use thereof
AU2023251091A1 (en) * 2022-04-06 2024-10-10 Gilead Sciences, Inc. Engineered cd200r antibodies and uses thereof
CN115458048B (zh) * 2022-09-16 2023-05-26 杭州美赛生物医药科技有限公司 基于序列编解码的抗体人源化方法
IL325073A (en) 2023-06-02 2026-02-01 Aimed Bio Inc Anti-CD200R1 antibody and its uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368535B2 (en) * 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer
US8075884B2 (en) * 2006-01-12 2011-12-13 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
KR20090094846A (ko) * 2006-12-22 2009-09-08 쉐링 코포레이션 Cd200r에 대한 항체
JP6012473B2 (ja) * 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ, インコーポレイテッド 抗cd200抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
BR112012020101A2 (pt) * 2010-02-11 2018-09-25 Alexion Pharma Inc método diagnósticos e terapêuticos usando anticorpos anti-cd200.
WO2015057906A1 (en) 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists

Also Published As

Publication number Publication date
NZ773626A (en) 2024-11-29
PH12021550530A1 (en) 2022-02-14
SG11202101697YA (en) 2021-04-29
MA53604A (fr) 2021-12-22
ZA202101246B (en) 2023-04-26
US20220251198A1 (en) 2022-08-11
JOP20210048A1 (ar) 2021-03-11
JP2024105529A (ja) 2024-08-06
CO2021003093A2 (es) 2021-03-19
CN112739422A (zh) 2021-04-30
IL281442A (en) 2021-04-29
MX2021003026A (es) 2021-05-27
KR20210044262A (ko) 2021-04-22
CA3112763A1 (en) 2020-03-19
TW202024132A (zh) 2020-07-01
IL281442B1 (en) 2023-11-01
AU2019339334B2 (en) 2023-03-09
PE20211742A1 (es) 2021-09-06
JP2022500080A (ja) 2022-01-04
JP7490025B2 (ja) 2024-05-24
EP3849667A1 (en) 2021-07-21
AU2019339334A1 (en) 2021-03-18
ECSP21017619A (es) 2021-04-29
CN112739422B (zh) 2024-05-28
IL281442B2 (en) 2024-03-01
JP2022141959A (ja) 2022-09-29
KR102705378B1 (ko) 2024-09-12
CN118530360A (zh) 2024-08-23
MY196156A (en) 2023-03-17
US11319370B2 (en) 2022-05-03
DOP2021000040A (es) 2021-03-31
US20200087395A1 (en) 2020-03-19
TWI749367B (zh) 2021-12-11
AR116668A1 (es) 2021-06-02
ZA202204978B (en) 2022-09-28
JOP20210048B1 (ar) 2024-12-22
JP7185051B2 (ja) 2022-12-06
WO2020055943A1 (en) 2020-03-19
CA3112763C (en) 2024-05-14
BR112021003254A2 (pt) 2021-05-18
CL2021000606A1 (es) 2021-09-20
EA202190530A1 (ru) 2021-06-21

Similar Documents

Publication Publication Date Title
ECSP21017619A (es) Anticuerpos agonistas contra cd200r y sus usos
PH12019500408A1 (en) Asid-alpha glucosidase variants and uses thereof
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
MX383130B (es) Composiciones que comprenden cepas bacterianas del genero megasphaera y sus usos.
MX391279B (es) Anticuerpos biespecíficos contra cd3 y cd20.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
CO2022006708A2 (es) Anticuerpos trem2 y usos de estos
ZA201902140B (en) Acid-alpha glucosidase variants and uses thereof
GT201700188A (es) Anticuerpos contra tau y sus usos
PA8799001A1 (es) Anticuerpos que se unen a il-4 y/o el-13 y sus usos
MX2023005484A (es) Analogos de carbamoil fenilalaninol y usos de los mismos.
PH12019500751A1 (en) Carbamoyl phenylalaninol compounds and uses thereof
MX2019006917A (es) Montajes de muelle helicoidal abierto.
TN2018000289A1 (en) Antibodies for il-17c
MX2022015456A (es) Composiciones de maca y metodos de uso.
PH12017500613A1 (en) Improved peptide inhibitors of sodium channels
CO2018007236A2 (es) Reguladores cftr y métodos de uso
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.
CR20190176A (es) Usos de antagonistas de il-13 para el tratamiento de dermatitis atópica
DOP2019000082A (es) Anticuerpos anti-il-33 y usos de los mismos
GT200800048A (es) Anticuerpos humanos contra il13 y usos terapeuticos